Victory Capital Management Inc. raised its holdings in Equillium (NYSE:EQ) by 7.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,323,381 shares of the company’s stock after buying an additional 90,792 shares during the quarter. Victory Capital Management Inc. owned approximately 0.08% of Equillium worth $10,587,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. American International Group Inc. purchased a new stake in Equillium in the 4th quarter valued at about $28,000. Deutsche Bank AG purchased a new stake in Equillium in the 4th quarter valued at about $54,000. Partner Investment Management L.P. purchased a new stake in Equillium in the 4th quarter valued at about $64,000. Geode Capital Management LLC purchased a new stake in Equillium in the 4th quarter valued at about $143,000. Finally, Dean Capital Investments Management LLC purchased a new stake in Equillium in the 4th quarter valued at about $175,000.

Several analysts have commented on EQ shares. Leerink Swann started coverage on Equillium in a report on Friday, February 22nd. They issued an “outperform” rating for the company. Svb Leerink reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Equillium in a research note on Friday, February 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Equillium currently has an average rating of “Buy” and an average price target of $19.00.

Shares of NYSE EQ traded down $0.11 during midday trading on Wednesday, hitting $7.62. The stock had a trading volume of 3,484 shares, compared to its average volume of 27,251. Equillium has a 1-year low of $5.12 and a 1-year high of $19.69.

Equillium (NYSE:EQ) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04).

TRADEMARK VIOLATION WARNING: “Equillium (EQ) Holdings Increased by Victory Capital Management Inc.” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://theolympiareport.com/2019/05/22/equillium-eq-holdings-increased-by-victory-capital-management-inc.html.

Equillium Company Profile

Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Featured Story: What are Bollinger Bands?

Want to see what other hedge funds are holding EQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Equillium (NYSE:EQ).

Institutional Ownership by Quarter for Equillium (NYSE:EQ)

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.